Genital human papillomavirus infections: Current and prospective therapies

Journal of General Virology

Volumn 93, Issue 4, 2012, Pages 681-691

  Stanley, Margaret A ^a  

^a Department of Pathology ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CARRAGEENAN; CIDOFOVIR; COMPLEMENTARY RNA; GLYCOPROTEIN E1; IMIQUIMOD; LOPINAVIR PLUS RITONAVIR; PEPTIDE APTAMER; PLACEBO; PODOPHYLLOTOXIN; POLYPHENON E; PROTEIN E2; PROTEIN E6; PROTEIN E7; PROTEIN P53; RIBOZYME; SMALL INTERFERING RNA; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ANUS CANCER; ANUS INTRAEPITHELIAL NEOPLASIA; CANCER IMMUNOTHERAPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EDEMA; ERYTHEMA; EXCISION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; MUCOSAL IMMUNITY; NONHUMAN; PAIN; PRECANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PRURITUS; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VAGINA INTRAEPITHELIAL NEOPLASIA; VIRUS CARCINOGENESIS; VIRUS ENTRY; VIRUS GENOME; VIRUS LATENCY; VIRUS PATHOGENESIS; VULVA CANCER; VULVA INTRAEPITHELIAL NEOPLASIA;

ANTIVIRAL AGENTS; ANUS DISEASES; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 84858175257     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.039677-0     Document Type: Review

References (92)

1. Abbate, E. A., Voitenleitner, C. & Botchan, M. R. (2006). Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol Cell 24, 877-889.
2. Abramson, A. L., Nouri, M., Mullooly, V., Fisch, G. & Steinberg, B. M. (2004). Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 72, 473-477.
3. Ahmad, N., Gupta, S. & Mukhtar, H. (2000). Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kBin cancer cells versus normal cells. Arch Biochem Biophys 376, 338-346.
4. Amin, A. A., Titolo, S., Pelletier, A., Fink, D., Cordingley, M. G. & Archambault, J. (2000). Identification of domains of the HPV11 E1 protein required for DNA replication in vitro. Virology 272, 137-150.
5. Arbyn, M., Castellsague, X., de Sanjose, S., Bruni, L., Saraiya, M., Bray, F. & Ferlay, J. (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22, 2675-2686.
6. Batman, G., Oliver, A. W., Zehbe, I., Richard, C., Hampson, L. & Hampson, I. N. (2011). Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir Ther 16, 515-525.
7. Be, X., Hong, Y., Wei, J., Androphy, E. J., Chen, J. J. & Baleja, J. D. (2001). Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 40, 1293-1299.
8. Beltz, L. A., Bayer, D. K., Moss, A. L. & Simet, I. M. (2006). Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6, 389-406.
9. Bernard, H. U., Burk, R. D., Chen, Z., van Doorslaer, K., Hausen, H. Z. & de Villiers, E. M. (2010). Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401, 70-79.
10. Beutner, K. R., Tyring, S. K., Trofatter, K. F. J., Jr, Douglas, J. M. J., Jr, Spruance, S., Owens, M. L., Fox, T. L., Hougham, A. J. & Schmitt, K. A. (1998). Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 42, 789-794.
11. Cao, Y., Zhao, J., Yang, Z., Cai, Z., Zhang, B., Zhou, Y., Shen, G. X., Chen, X., Li, S. & Huang, B. (2010). CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 136, 21-29.
12. Chiang, C. M., Ustav, M., Stenlund, A., Ho, T. F., Broker, T. R. & Chow, L. T. (1992). Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci USA 89, 5799-5803.
13. Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107, 4275-4280.
14. D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H. & Gillison, M. L. (2007). Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356, 1944-1956.
15. Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L. & Kitchener, H. C. (2010). Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102, 1129-1136.
16. De Vuyst, H., Lillo, F., Broutet, N. & Smith, J. S. (2008). HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17, 545-554.
17. Dillner, J., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Perez, G., Brown, D. R., Koutsky, L. A. & other authors (2010). Four year efficacy of prophylactic human papillo-mavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ 341, c3493.
18. Donne, A. J., Hampson, L., He, X. T., Day, P. J., Salway, F., Rothera, M. P., Homer, J. J. & Hampson, I. N. (2009). Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antivir Ther 14, 939-952.
19. Doorbar, J. (2005). The papillomavirus life cycle. J Clin Virol 32 (Suppl. 1), S7-S15.
20. Faucher, A. M., White, P. W., Brochu, C., Grand-Mattre, C., Rancourt, J. & Fazal, G. (2004). Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. J Med Chem 47, 18-21.
21. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T. & other authors (2010). Selective inhibition of BET bromodomains. Nature 468, 1067-1073.
22. Fouts, E. T., Yu, X., Egelman, E. H. & Botchan, M. R. (1999). Biochemical and electron microscopic image analysis of the hexameric E1 helicase. J Biol Chem 274, 4447-4458.
23. Fox, P. A., Nathan, M., Francis, N., Singh, N., Weir, J., Dixon, G., Barton, S. E. & Bower, M. (2010). A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS 24, 2331-2335.
24. Fradet-Turcotte, A. & Archambault, J. (2007). Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther 12, 431-451.
25. Gagnon, D., Joubert, S., Senechal, H., Fradet-Turcotte, A., Torre, S. & Archambault, J. (2009). Proteasomal degradation of the papillo-mavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4. J Virol 83, 4127-4139.
26. Goudreau, N., Cameron, D. R., Deeziel, R., Hache, B., Jakalian, A., Malenfant, E., Naud, J., Ogilvie, W. W., O'meara, J. & other authors (2007). Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg Med Chem 15, 2690-2700.
27. Govan, V. A. (2005). Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann N YAcad Sci 1056, 328-343.
28. Hampson, L., Kitchener, H. C. & Hampson, I. N. (2006). Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 11, 813-825.
29. Hegde, R. S. (2002). The papillomavirus E2 proteins: structure, function, and biology. Annu Rev Biophys Biomol Struct 31, 343-360.
30. Herdman, M. T., Pett, M. R., Roberts, I., Alazawi, W. O., Teschendorff, A. E., Zhang, X. Y., Stanley, M. A. & Coleman, N. (2006). Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27, 2341-2353.
31. Ilves, I., Kivi, S. & Ustav, M. (1999). Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites. J Virol 73, 4404-4412.
32. Ingle, A., Ghim, S., Joh, J., Chepkoech, I., Bennett Jenson, A. & Sundberg, J. P. (2011). Novel laboratory mouse papillomavirus (MusPV) infection. Vet Pathol 48, 500-505.
33. Jablonska, S., Dabrowski, J. & Jakubowicz, K. (1972). Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 32, 583-589.
34. Jones, R. W. (2001). Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 22, 393-402.
35. Kenter, G. G., Welters, M. J., Valentijn, A. R., Lowik, M. J., Berends-van der Meer, D. M., Vloon, A. P., Essahsah, F., Fathers, L. M., Offringa, R. & other authors (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361, 1838-1847.
36. Khan, N., Afaq, F., Saleem, M., Ahmad, N. & Mukhtar, H. (2006). Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 66, 2500-2505.
37. Kim, D. H., Jarvis, R. M.,Xu, Y., Oliver, A. W., Allwood, J. W., Hampson, L., Hampson, I. N. & Goodacre, R. (2010). Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst (Lond) 135, 1235-1244.
38. Kines, R. C., Thompson, C. D., Lowy, D. R., Schiller, J. T. & Day, P. M. (2009). The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 106, 20458-20463.
39. Kjaer, S. K., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H. & other authors (2009). A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2, 868-878.
40. Koutsky, L. (1997). Epidemiology of genital human papillomavirus infection. Am J Med 102 (5A), 3-8.
41. Lacey, C. J. (2005). Therapy for genital human papillomavirus-related disease. JClin Virol 32 (Suppl. 1), S82-S90.
42. Lacey, C. J., Lowndes, C. M. & Shah, K. V. (2006). Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/ 11 disease. Vaccine 24 (Suppl. 3), S35-S41.
43. Liu, Y., Liu, Z., Androphy, E., Chen, J. & Baleja, J. D. (2004). Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry 43, 7421-7431.
44. Lusky, M., Hurwitz, J. & Seo, Y. S. (1994). The bovine papillomavirus E2 protein modulates the assembly of but is not stably maintained in a replication-competent multimeric E1-replication origin complex. Proc Natl Acad Sci U S A 91, 8895-8899.
45. Masterson, P. J., Stanley, M. A., Lewis, A. P. & Romanos, M. A. (1998). A C-terminal helicase domain of the human papillomavirus El protein binds E2 and the DNA polymerase alpha-primase p68 subunit. J Virol 72, 7407-7419.
46. Maw, R. (2004). Critical appraisal of commonly used treatment for genital warts. Int J STD AIDS 15, 357-364.
47. McBride, A. A., McPhillips, M. G. & Oliveira, J. G. (2004). Brd4: tethering, segregation and beyond. Trends Microbiol 12, 527-529.
48. Meyers, C., Mayer, T. J. & Ozbun, M. A. (1997). Synthesis of infectious human papillomavirus type 18 in differentiating epithelium trans-fected with viral DNA. J Virol 71, 7381-7386.
49. Moody, C. A. & Laimins, L. A. (2010). Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10, 550-560.
50. Moore, R. A., Nicholls, P. K., Santos, E. B., Gough, G. W. & Stanley, M. A. (2002). COPV DNA absence following prophylactic Ll PMID vaccination. J Gen Virol 83, 2299-2301.
51. Moscicki, A. B., Schiffman, M., Kjaer, S. & Villa, L. L. (2006). Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24 (Suppl. 3), S42-S51.
52. Nominee, Y., Masson, M., Charbonnier, S., Zanier, K., Ristriani, T., Deryckere, F., Sibler, A. P., Desplancq, D., Atkinson, R. A. & other authors (2006). Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21, 665-678.
53. Orth, G., Dompmartin, D., Agache, P., Favre, M. & Croissant, O. (1978). [Plurality of human papillomaviruses (author's transl)]. Ann Dermatol Venereol 105, 279-288.
54. Paavonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S. N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J. C. & other authors (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314.
55. Palefsky, J. M., Gillison, M. L. & Strickler, H. D. (2006). Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 24 (Suppl. 3), S140-S146.
56. Parkin, D. M. & Bray, F. (2006). Chapter 2: the burden of HPV-related cancers. Vaccine 24 (Suppl. 3), S11-S25.
57. Pett, M. R., Herdman, M. T., Palmer, R. D., Yeo, G. S., Shivji, M. K., Stanley, M. A. & Coleman, N. (2006). Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A 103, 3822-3827.
58. Prendiville, W. (1995). Large loop excision of the transformation zone. Clin Obstet Gynecol 38, 622-639.
59. Roberts, J. N., Buck, C. B., Thompson, C. D., Kines, R., Bernardo, M., Choyke, P. L., Lowy, D. R. & Schiller, J. T. (2007). Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13, 857-861.
60. Roberts, J. N., Kines, R. C., Katki, H. A., Lowy, D. R. & Schiller, J. T. (2011). Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst 103, 737-743.
61. Sanders, C. M. & Stenlund, A. (1998). Recruitment and loading of the E1 initiator protein: an ATP-dependent process catalysed by a transcription factor. EMBO J 17, 7044-7055.
62. Sapp, M. & Bienkowska-Haba, M. (2009). Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J 276, 7206-7216.
63. Schwartz, S. (2008). HPV-16 RNA processing. Front Biosci 13, 5880-5891.
64. Seo, Y. S., Muller, F., Lusky, M., Gibbs, E., Kim, H. Y., Phillips, B. & Hurwitz, J. (1993). Bovine papilloma virus (BPV)-encoded E2 protein enhances binding of E1 protein to the BPV replication origin. Proc Natl Acad Sci USA 90, 2865-2869.
65. Sharma, R. K., Elpek, K. G., Yolcu, E. S., Schabowsky, R. H., Zhao, H., Bandura-Morgan, L. & Shirwan, H. (2009). Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 69, 4319-4326.
66. Smith, J. A., White, E. A., Sowa, M. E., Powell, M. L., Ottinger, M., Harper, J. W. & Howley, P. M. (2010). Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc Natl Acad Sci U S A 107, 3752-3757.
67. Sonnex, C. & Lacey, C. J. (2001). The treatment of human papillomavirus lesions of the lower genital tract. Best Pract Res Clin Obstet Gynaecol 15, 801-816.
68. Stanley, M. A. (2002). Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27, 571-577.
69. Stanley, M. (2006). Immune responses to human papillomavirus. Vaccine 24 (Suppl. 1), S16-S22.
70. Su, J. H., Wu, A., Scotney, E., Ma, B., Monie, A., Hung, C. F. & Wu, T. C. (2010). Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 24, 109-129.
71. Talis, A. L., Huibregtse, J. M. & Howley, P. M. (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. JBiol Chem 273, 6439-6445.
72. Tatti, S., Stockfleth, E., Beutner, K. R., Tawfik, H., Elsasser, U., Weyrauch, P. & Mescheder, A. (2010). Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol 162, 176-184.
73. Terlou, A., van Seters, M., Ewing, P. C., Aaronson, N. K., Gundy, C. M., Heijmans-Antonissen, C., Quint, W. G., Blok, L. J., van Beurden, M. & Helmerhorst, T. J. (2011). Treatment ofvulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 121, 157-162.
74. Titolo, S., Pelletier, A., Sauve, F., Brault, K., Wardrop, E., White, P. W., Amin, A., Cordingley, M. G. & Archambault, J. (1999). Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin. JVirol 73, 5282-5293.
75. Titolo, S., Pelletier, A., Pulichino, A. M., Brault, K., Wardrop, E., White, P. W., Cordingley, M. G. & Archambault, J. (2000). Identification of domains of the human papillomavirus type 11 E1 helicase involved in oligomerization and binding to the viral origin. J Virol 74, 7349-7361.
76. Titolo, S., Brault, K., Majewski, J., White, P. W. & Archambault, J. (2003). Characterization of the minimal DNA binding domain of the human papillomavirus E1 helicase: fluorescence anisotropy studies and characterization of a dimerization-defective mutant protein. J Virol 77, 5178-5191.
77. Trimble, C. L. & Frazer, I. H. (2009). Development of therapeutic HPV vaccines. Lancet Oncol 10, 975-980.
78. Trimble, C. L., Clark, R. A., Thoburn, C., Hanson, N. C., Tassello, J., Frosina, D., Kos, F., Teague, J., Jiang, Y. & other authors (2010). Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 185, 7107-7114.
79. van der Burg, S. H., Piersma, S. J., de Jong, A., van der Hulst, J. M., Kwappenberg, K. M., van den Hende, M., Welters, M. J., Van Rood, J. J., Fleuren, G. J. & other authors (2007). Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 104, 12087-12092.
80. + by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115, 69-74.
81. Viera, M. H., Amini, S., Huo, R., Konda, S., Block, S. & Berman, B. (2010). Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options. Int J Dermatol 49, 733-749.
82. von Krogh, G., Lacey, C. J., Gross, G., Barrasso, R. & Schneider, A. (2000). European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 76, 162-168.
83. Welters, M. J., Kenter, G. G., de Vos van Steenwijk, P. J., Lowik, M. J., Berends-van der Meer, D. M., Essahsah, F., Stynenbosch, L. F., Vloon, A. P., Ramwadhdoebe, T. H. & other authors (2010). Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107, 11895-11899.
84. White, P. W., Pelletier, A., Brault, K., Titolo, S., Welchner, E., Thauvette, L., Fazekas, M., Cordingley, M. G. & Archambault, J. (2001). Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain. J Biol Chem 276, 22426-22438.
85. White, P. W., Faucher, A. M., Massariol, M. J., Welchner, E., Rancourt, J., Cartier, M. & Archambault, J. (2005). Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 49, 4834-4842.
86. White, P. W., Faucher, A. M. & Goudreau, N. (2011). Small molecule inhibitors of the human papillomavirus E1-E2 interaction. Curr Top Microbiol Immunol 348, 61-88.
87. Woo, Y. L., van den Hende, M., Sterling, J. C., Coleman, N., Crawford, R. A., Kwappenberg, K. M., Stanley, M. A. & van der Burg, S. H. (2010). A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6-and E7-specific T-cell responses. Int J Cancer 126, 133-141.
88. Yang, L., Li, R., Mohr, I. J., Clark, R. & Botchan, M. R. (1991). Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 353, 628-632.
89. Yang, G. Y., Liao, J., Kim, K., Yurkow, E. J. & Yang, C. S. (1998). Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19, 611-616.
90. Yoakim, C., Ogilvie, W. W., Goudreau, N., Naud, J., Hache, B., O'Meara, J. A., Cordingley, M. G., Archambault, J. & White, P. W. (2003). Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-origin DNA complex. Bioorg Med Chem Lett 13, 2539-2541.
91. Zhao, C. Y., Szekely, L., Bao, W. & Selivanova, G. (2010). Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 70, 3372-3381.
92. zur Hausen, H., de Villiers, E. M. & Gissmann, L. (1981). Papillomavirus infections and human genital cancer. Gynecol Oncol 12, S124-S128.